DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Back Matter (PDF) The Editor of the Journal of Pharmacology & Experimental Therapeutics wishes to express appreciation to the following colleagues who acted as Guest Editors for Specific Fields in 1987. Martin W. Adler Frank R. Goodman Elaine Sanders-Bush Lewis Aronow Robert Z. Gussin Lewis E. Seiden C. Paul Bianchi Conan Kornetsky Theodore J. Torphy Allan H. Conney Donald J. Jenden John L. Skosey Theodore J. Cicero Robert M. Joy Larry G. Stark Charles R. Craig Louis Lemberger Norman Weiner Gerard L. Gebber Benedict R. Lucchesi Wallace D. Winters James W. Gibb Donald V. Priola Dixon M. Woodbury Dora B. Goldstein Additionally, sincere thanks are due to 724 of our colleagues not on the Editorial Advisory Board who reviewed articles for the Journal in 1987. Their contributions are acknowledged individually in the Annual Report of The Journal to The Board of Publications Trustees of The American Society for Pharmacology and Experimental Therapeutics. INDEX Volume 245, April-June, 1988 A23187, effect ofextracellularcalcium omis- classification, ligand affmity and mo- -induced intoxication, effects of Ro15- sion, hepatocytes (rats), 493 lecular mass (bovine), 1060 4513 (rats), 880 Abhold, R. H. and Harding, J. W.: Metabo- imidazoline analogs, aorta (rats), 793 Mi, S. F., see Schulze, G. E., 178 lism of angiotensins II and III by inotropic positive effect, inositol tris- Alkondon, M., Rao, K. S. and Albuquerque, membrane-bound peptidases from phosphate increase in heart (rats), E. X.: Acetylcholinesterase reactiva- rat brain, 171 327 tom modify the functional properties Abiko, Y., see Hara, Y., 305 prazosin and indoramin, coronary of the nicotinic acetylcholine recep- Acetaminophen blood flow (dogs), 232 tor ion channel, 543 diminuition of hepatotoxicity, ethanol alpha-2 Allbee, W. E., see Kachur, J. F., 455 (rats), 129 effects of agonist, angiotensin convert- Allen, J. C., see Navran, S. S., 608 drug metabolite toxicity, human lympho- ing enzyme (guinea pigs), 932 Allescher, H.-C., see Daniel, E. E., 1002 cytes, cytochrome P-450 (rats), 956 idazoxan administration, blood pres- Aluminum, uptake, gut preparation (rats), inhibition ofconjugation, ranitidine, hep- sure (rats), 265 928 atotoxicity, 887 peripheral-acting antagonist (rats), 32 Amino acids Acetylcholinesterase presynaptic autoinhibition, central nor- excitatory muscarimc responses of AF-DX 116, su- adrenaline release (rats), 944 cAMP accumulation, role of chloride perior cervical ganglion (rabbits), 419 receptor subtypes, antagonist binding (guinea pigs), 299 reactivators, nicotinic acetylcholine re- (humans), 600 phencyclidine-like behavior, MK-801 ceptor ion channel (frogs), 543 alpha and beta, brown fat adenylate cy- (pigeons, rats, monkeys), 969 N-Acetylcysteine, pharmacologic interac- clase, norepinephrine (rats), 1075 Aminobenzotriazole, pulmonary clearance, tion, organic nitrates with thiols beta vasoactive drugs (rats), 402 (rats), 524 discriminative stimulus, clenbuterol -y-Aminobutyric acid Adair, S. E., see Navran, S. S., 608 (rats), 155 effects of Ro15-4513, intoxication, alco- Adams, L. M., see Rimele, T. J., 102 large coronary arteries (dogs), 936 hol-induced (rats), 880 Adejare, A., see Lamba-Kanwal, V. K., 793 stereospecificity, antagonists (rabbits), elimination of, osmotic shock (rats), 342 Adenosine triphosphatase, sodium-potas- 94 enhanced release by clonidine, alpha sium, norepinephrine release, kidney beta-i, homogeneous population, bovine adrenoceptors, cerebral cortex subre- (rats), 436 coronary artery (cows, guinea pigs, gions (rats), 682 Adenylate cyclase and rabbits), 67 receptor response, benzodiazepines, en- inhibition, muscarinic receptors, neos- AF-DX 1 16, muscarinic responses, superior teric nervous system (guinea pigs), triatum (rats), 658 cervical ganglion (rabbits), 419 250 responsiveness, norepinephrine, brown Affective disorders, effects of trihexypheni- Aminoglycosides, effects of antibiotics, neu- adipose tissue (rats), 1075 dyl and carbamazepine, substance P ronal calcium uptake (rats), 389 somatostatin receptor coupling, multiple and haloperidol, brain (rats), 982 Amione, J., see Szeto, H. H., 537 effector systems (mice), 225 Aging Amitriptyline stereoselectivity, ocular beta receptors effect of phenytoin and smoking, theoph- antihistaminic and antimuscarinic ef- (rabbits), 94 ylline oxidation and cortisol, healthy fects, ileal electrolyte transport, mus- stimulatory regulatory protein, neural men, 513 cle contractility (guinea pigs), 455 modulation, brown adipose tissue effects on neurotransmission, cardiac experimental poisoning, phenytoin pro- (rats), 1068 sympathetic neuroeffector junction phylaxis, cardiotoxicity (dogs), 216 Adgate, L., see Atchison, W. D., 394 (rats), 798 Amphetamine Adipose tissue inhibition of norepinephrine contrac- phenylethylamine and related drugs, do- brown tions, aorta and pulmonary artery, pamine release, mazindol binding adenylate cyclase, stimulatory regula- diltiazem (rats), 1016 (rabbits), 199 tory protein (rats), 1068 Ahmad, S., see Daniel, E. E., 1002 ventral mesencephalon injection, sensi- norepinephrine, adenylate cyclase re- AHR 11325, histamine H, antagonists, be- tivity, peripheral amphetamine and sponsiveness (rats), 1075 havioral effects, compared to halo- cocaine (rats), 1095 Adler, M. W., see Gochin, P. M., 569 peridol (monkeys), 471 Amphotericin B, adverse effect on renal Adrenal glands, norepinephrine content in Airway hemodynamics (rats), 594 tissues, time course (rats), 24 smooth muscle relaxation, peripheral type Analgesia Adrenoceptors benzodiazepine receptor (guinea effects of DPDYN (mice), 995 alpha pigs), 557 -endorphin-induced, intrathecal fl-fun- clonidine, ‘y-axninobutyric acid release smooth muscle volume and contractile re- altrexamine (mice), 587 (rats), 682 sponse (rabbits), 687 oxymetazoline-induced, tolerance, cross- cooling, central ear artery (rabbits), 89 Alaranta, S., see Klinge, E., 280 tolerance to intrathecal morphine inhibited norepinephrine contractions, Albrightson-Winslow, C. R., see Brooks, D. (rats), 319 diltiazem (rats), 1016 P., 211 pharmacology of SCH 34826 (mice), 829 receptor reserve, calcium channel Albuquerque, E. X., see Alkondon, M., 543 supraspinal and spinal opioid, Mu recep- blockers in vascular tissues (rats), Alcohol tor (mice), 13 673 chronic effects, pituitary and ovarian hor- Analgesics sodium pump stimulation, blood vessels mones, healthy women, 407 narcotic, efficacy and tolerance, mu (dogs), 608 effects on naloxone-stimulated luteiniz- opioid receptor (humans), 350 spinal vs. peripheral pharmacology, ing hormone, follicle-stimulating opiate agonists and antagonists, i4-hy- micturition (rats), 426 hormone, prolactin plasma levels droxydihydromorphinone hydra- alpha-i (monkey), 895 zones (mice), 8 1111 1112 Index Vol. 245 Andersen, M. E., see D’Souza, R. W., 563 sponse in airway tissue. Isometric acute and daily cocaine administration Andersson, R. G. G., see Lindgren, B. R., versus isotonic measurement, 687 (rats), 485 932 Artery effects of levorphanol, kappa-selective Anesthetics caudal, norepmephrine content in tissues, opioids (monkeys), 364 neuronal intracellular calcium concentra- time course (rats), 24 genetic factors in ethanol reinforcement tions, membrane fluidization (mice), central ear, cooling (rabbits), 89 (rats), 164 1 coronary performance in battery of complex oper- reduction of V,,,,,,, benzocaine, cardiac beta adrenoceptors (dogs), 936 ant tests, acute effects, tetrahydro- Purkinje fibers (dogs), 381 homogeneous population, beta-i adren- cannabinol (monkeys), 178 Angiotensin converting enzyme oceptors (cows, guinea pigs, and rab- phencyclidine-like, MK-801 (pigeons, apha-2 adrenoceptor agonist, clonidine, bits), 67 rats, monkeys), 969 inflammation (guinea pigs), 932 ischemic myocardial acidosis, MCI-176 Benavides, J., Peny, B., DuBois, A., Per- inhibition by perindopril (rats), 950 (dogs), 305 rault, G., Morel, E., Zivkovic, B. and Angiotensins II and III, metabolism by mesenteric Scatton, B.: In vivo interaction of membrane-bound peptidases, brain leukotriene D4 vasomotor relaxation, zolpidem with central benzodiaze- cGMP (dogs), 47 (rats), 171 pine (BZD) binding sites (as labeled norepinephrine content in tissues, time Antagonists, beta adrenergic, stereospecific- by [3H]RO 15-1788) in the mouse course (rats), 24 ity, ciliary process (rabbits), 94 brain. Preferential affmity of zolpi- vasodilation, minoxidril sulfate-in- Antibiotics dem for the w, (BZD,) subtype, 1033 duced (rabbits), 751 cephalosporin, mitochondrial respiratory Bennett, B. M., see Schroder, H., 413 pulmonary, inhibited norepinephrine toxicity (rabbits), 1054 Benzocaine, reduction of V, cardiac Pur- contractions, diltiazem (rats), 1016 effects on calcium uptake, isolated nerve kinje fibers (dogs), 381 route of delivery, liver extraction, vitamin terminals (rats), 389 Benzodiazepines D3 (rats), 975 Anticonvulsants, tetrazepam, psychophar- binding sites, interaction of zolpidem, Ashe, J. H., see Yarosh, C. A., 419 macological profile (rats, mice), 692, brain (mice), 1033 Aspirin 699 nonlinear pharmacokinetics (rats), 809 cerebral uptake, lipophilicity, plasma pro- Antidepressants tein binding (rats), 816 oral vs. i.v., inhibitor of cyclooxygenase discriminative stimulus properties, den- effect of experimental hypovolemia, des- activity, portacaval shunt (rats), 287 buterol (rats), 155 pyrogenic properties of tumor necrosis methyldiazepam (rats), 508 patterns of administration, antinocicep- factor (rabbits), 336 GABAA receptor response, enteric nerv- tive action,
Load more

Recommended publications
  • The Metamorphosis of Hydromorphone Gary M
    Pharmacy PersPective The metamorphosis of hydromorphone Gary M. Reisfield, MD George R. Wilson, MD introduction “That’s it. The Mayo Clinic at Rochester devel - oped it, the word and the drug, for it means a Hydromorphone hydrochloride, one of the oldest of drug, a pain relieving drug, five times as potent the extant opioid analgesics, has been in clinical use for as morphine, as harmless as water and with no more than 70 years. Its use by the oral route in chronic habit forming qualities. pain and hospice/palliative medicine settings has been limited, however, largely owing to its relatively short “The medical journals say it is particularly useful duration of action. With the recent US Food and Drug in the operation of cases where other drugs Administration (FDA) approval of a once-daily extended- seem to offer no relief from pain. Unlike mor - release formulation of the drug (Palladone, Purdue phine, there are no pleasurable sensations to its Pharma LP, Stamford, CT), hydromorphone joins mor - use, however, and if the doctors reckon correctly phine, oxycodone, and fentanyl as the only extended- its use may go far toward curing addicts of the release opioids available on the United States market. morphine habit.” Here, we review the history, pharmacokinetics, and other relevant issues concerning this invaluable opioid, and Montgomery (AL) Advertiser , Dec. 18, 1932 also discuss the role of the new formulation in the man - agement of chronic pain. From 1929 to 1939, the National Research Council’s Committee on Drug Addiction conducted exhaustive history research on the morphine molecule and its analogs, pro - ducing more than 150 semisynthetic and more than 300 Hydromorphone [also Dilaudid (Knoll Laboratories, synthetic compounds, of which more than 30 were tested Mount Olive, NJ), dihydromorphinone, dihydromorphe - clinically.
    [Show full text]
  • Morphinone Reductase for the Preparation Of
    Europäisches Patentamt *EP000649465B1* (19) European Patent Office Office européen des brevets (11) EP 0 649 465 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C12N 9/02, C12P 17/18, of the grant of the patent: C12Q 1/32 24.07.2002 Bulletin 2002/30 (86) International application number: (21) Application number: 93913236.1 PCT/GB93/01129 (22) Date of filing: 28.05.1993 (87) International publication number: WO 94/00565 (06.01.1994 Gazette 1994/02) (54) MORPHINONE REDUCTASE FOR THE PREPARATION OF HYDROMORPHONE AND HYDROCODONE MORPHINONE REDUKTASE ZUR HERSTELLUNG VON HYDROMORPHONE UND HYDROCODONE MORPHINONE REDUCTASE DESTINEE A LA PREPARATION D’HYDROMORPHONE ET D’HYDROCODONE (84) Designated Contracting States: (74) Representative: Perry, Robert Edward AT BE CH DE DK ES FR GB IE IT LI NL PT SE GILL JENNINGS & EVERY Broadgate House (30) Priority: 25.06.1992 GB 9213524 7 Eldon Street London EC2M 7LH (GB) (43) Date of publication of application: 26.04.1995 Bulletin 1995/17 (56) References cited: WO-A-90/13634 (73) Proprietor: MACFARLAN SMITH LIMITED Edinburgh EH11 2QA (GB) • THE BIOCHEMICAL JOURNAL vol. 274, no. 3, 15 March 1991, pages 875 - 880 NEIL C. BRUCE ET (72) Inventors: AL. ’Microbial degradation of the morphine • HAILES, Anne, Maria 59 Lower Road alkaloids. Purification and characterization of Kent DA8 1AY (GB) morphine dehydrogenase from Pseudomonas • FRENCH, Christopher, Edward putida M10’ Palmerston North (NZ) • BRUCE, Neil, Charles Cambridge CB2 1ND (GB) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Microbial Degradation of the Morphine Alkaloids Purification and Characterization of Morphine Dehydrogenase from Pseudomonas Putida M10
    Biochem. J. (1991) 274, 875-880 (Printed in Great Britain) 875 Microbial degradation of the morphine alkaloids Purification and characterization of morphine dehydrogenase from Pseudomonas putida M10 Neil C. BRUCE,* Clare J. WILMOT, Keith N. JORDAN, Lauren D. Gray STEPHENS and Christopher R. LOWE Institute of Biotechnology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QT, U.K. The NADP+-dependent morphine dehydrogenase that catalyses the oxidation of morphine to morphinone was detected in glucose-grown cells of Pseudomonas putida M 10. A rapid and reliable purification procedure involving two consecutive affinity chromatography steps on immobilized dyes was developed for purifying the enzyme 1216-fold to electrophoretic homogeneity from P. putida M 10. Morphine dehydrogenase was found to be a monomer of Mr 32000 and highly specific with regard to substrates, oxidizing only the C-6 hydroxy group of morphine and codeine. The pH optimum of morphine dehydrogenase was 9.5, and at pH 6.5 in the presence of NADPH the enzyme catalyses the reduction of codeinone to codeine. The Km values for morphine and codeine were 0.46 mm and 0.044 mm respectively. The enzyme was inhibited by thiol-blocking reagents and the metal-complexing reagents 1, 10-phenanthroline and 2,2'-dipyridyl, suggesting that a metal centre may be necessary for activity of the enzyme. INTRODUCTION EXPERIMENTAL The morphine alkaloids have attracted considerable attention Materials owing to their analgaesic properties and, consequently, much Mimetic Orange 3 A6XL and Mimetic Red A6XL were effort in the past has been directed at the production of new obtained from Affinity Chromatography Ltd., Freeport, morphine alkaloids by micro-organisms (lizuka et al., 1960, Ballasalla, Isle of Man, U.K.
    [Show full text]
  • NOTIFICATION SPECIFYING SMALL QUANTITY and COMMERCIAL QUANTITYI Ly of the Pozoersconferred (Xxiiiil
    NOTIFICATION SPECIFYING SMALL QUANTITY AND COMMERCIAL QUANTITYI ly of the pozoersconferred (xxiiiil . - lleyise by clansesfuiia) and of section2 of the Nnrcotic Drrtgsnnd pnlchotropic SrtbstancesAct, 19g5 (61 of 1985)and in supersessionof Ministry of Ftnnnce, (D Departmentof'Reuenue Noiification s.o.527 aotra i'6tt,1uli, tssi, exceptas respects things doneor omitted to be done .beforesuch supersession,the Cential Gooernmenihereby spectfiesthe qtnntitrl ,nlnt'ionedin coltnnnsS and 6 of the Tablebelow, in relationto.the narcoticdrug or psychotropicsubstnnce mentioned.ii tlr', ,1urrponding entnl in columns2 to 4 of thesaid Table,as the small quantitrl nnd commercialquantity respectiailyfor the purposesof the said clnuse:sof ttrit seciion. TABLE [Seesub-clause vii(a) and xxiii(a) of section 2 of the Act] Sl No. Name of Narcotic Drug and Other non-proprietary Chemical Name Small Commercial Psychotropic Substance name Quanti- Quantity (Intemational non-proprietary ity (in (in gm./kg.) name (INN) Acetorphine 3-0-acetyltetrahydro-7-alpha-(l-hydroxy-l- methylbutyt)-o, l4-endoetheno-onpavine $ 50 9.. 1\) Acetyl-alpha-methylfen N-[-(alpha-methylphenethyl)-4-piperidy]l acetanilide 0.1 g-. J. Acetyldihydrocodeine 100 4. Acetylmethadol 3-acetoxy-6-dimethylamino-4, 4 lheptane 50 gm. 5. Alfentanil -ethyl-4, N-[1-[2-( 5-dihydro-S-oxo-lH-tetrazol-t-yt) 01 gm. ethyll-4-(methoxymethyl)-4-piperidinyll -N- ylpropanamide Allyprodine 3-allyl Jmethyl-4-phenyl-4 Alpha-3-acetoxy-6-dimethylamino-4,Ld lheptane 100 gm Alpha-3-ethyl-l-methyl-4-phenyl-4-propionox 50 gm. 9.7' AlphamethadolArPnametnaool Alpha-6-dimethylamino-4, 4-diphenyl-3-heptanol 2 S0 gm. 10. Alphu-*"thylf"ntur,yl 11.
    [Show full text]
  • 0 Cover Part Two\374
    PART TWO DEUXIÈME PARTIE SEGUNDA PARTE ﺍﳉﺰﺀ ﺍﻟﺜﺎﱐ 第二部分 ЧАСТЬ ВТΟΡАЯ - (...), [...] - (-)-3-hidroxi-N- (-)-(2R)-N-méthyl-1- fenacilmorfinán → Levophenacyl-morphan phénylpropan-2-amine → Levometamfetamine (-)-3-hidroxi-N- (-)-(3S,6R)-6- metilmorfinán → Levorphanol (dimethylamino)-4,4- (-)-3-hydroksymorfinan → Norlevorphanol diphenyl-3-heptanol → Betamethadol (-)-3-hydroksy-N- (-)-(3S,6R)-6- fenacylmorfinan → Levophenacyl-morphan (dimethylamino)-4,4- (-)-3-hydroksy-N- diphenyl-3-heptanol metylmorfinan → Levorphanol acetate (ester) → Betacetylmethadol (-)-3-hydroxymorphinan → Norlevorphanol (-)-(5R)-4,5-epoxy-3- (-)-3-hydroxy-N- methoxy-9α-methyl methylmorphinan → Levorphanol → Thebacon morphin-6-en-6-yl acetate (-)-3-hydroxynormorphinan → Norlevorphanol (-)-(5R,6S)-3-benzyloxy-4,5- (-)-3-hydroxy-N- epoxy-9a-methylmorphin- phenacylmorphinan → Levophenacyl-morphan 7-en-6-yl myristate → Myrophine (-)-3-hydroxytropane-2- (-)-(5R,6S)-4,5-epoxy carboxylat → Ecgonine morphin-7-en-3,6-diol → Normorphine (-)-3-idrossi-N- (-)-(5R,6S,14S)-4,5-epoxy- metilmorfinano → Levorphanol 14-hydroxy-3-methoxy- (-)-3-methoxy-N- 9a-methylmorphinan-6- methylmorphinan → Levomethorphan one → Oxycodone (-)-3-metil-2,2-difenil-4- (-)-(R)-4,5-epoxy-3- morfolinbutirilpirrolidina → Levomoramide methoxy-9a-methyl (-)-3-metoksy-N- morphinan-6-one → Hydrocodone metylmorfinan → Levomethorphan (-)-(R)-6-(dimethylamino)- (-)-3-metossi-N-metil- 4,4-diphenyl-3-heptanone → l-methadone morfinano → Levomethorphan (-)-(R)-N,α-dimethyl (-)-3-metoxi-N- phenethylamine → Levometamfetamine
    [Show full text]
  • Ep 2398808 B1
    (19) TZZ ¥Z_T (11) EP 2 398 808 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 489/08 (2006.01) 20.11.2013 Bulletin 2013/47 (86) International application number: (21) Application number: 10704301.0 PCT/US2010/024372 (22) Date of filing: 17.02.2010 (87) International publication number: WO 2010/096416 (26.08.2010 Gazette 2010/34) (54) Process for the reductive alkylation of normorphinans VERFAHREN ZUR REDUKTIVEN ALKYLIERUNG VON NORMORPHINANEN Procédé d’alkylation réductrice des normorphinanes (84) Designated Contracting States: • WOODS, Sharon AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Florissant HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Missouri 63034 (US) PT RO SE SI SK SM TR (74) Representative: Beckmann, Claus (30) Priority: 17.02.2009 US 153021 P Kraus & Weisert Patent- und Rechtsanwälte (43) Date of publication of application: Thomas-Wimmer-Ring 15 28.12.2011 Bulletin 2011/52 80539 München (DE) (73) Proprietor: Mallinckrodt LLC (56) References cited: Hazelwood, MO 63042 (US) WO-A1-2006/035195 WO-A1-2009/012005 (72) Inventors: • HUDSON, Edmund, C. Clayton Missouri 63105 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Recent Advances in the Chemistry of Oripavine and Its Derivatives
    Advances in Bioscience and Biotechnology, 2014, 5, 704-717 Published Online July 2014 in SciRes. http://www.scirp.org/journal/abb http://dx.doi.org/10.4236/abb.2014.58084 Recent Advances in the Chemistry of Oripavine and Its Derivatives Sandor Hosztafi Institute of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary Email: [email protected] Received 2 May 2014; revised 16 June 2014; accepted 12 July 2014 Copyright © 2014 by author and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Oripavine is the major alkaloid of Papaver orientale. It is an important intermediate in the bio- synthesis of morphine alkaloids. Recently, new Papaver somniferum strains have been developed which accumulate thebaine and oripavine, but not morphine and codeine. Therefore, the chemi- stry of oripavine has been studied intensively to synthesize opioid pharmaceuticals such as oxy- morphone, naloxone and buprenorphine. Keywords Papaver orientale, Papaver somniferum, Oripavine, Thebaine, Top1 Poppy 1. Introduction Thebaine an alkaloid present in 0.2% - 0.8% in opium and a major constituent (90% of total alkaloid content) in Papaver bracteatum (which is morphine free), possesses little utility medically for two reasons: (a) its lack of the depressant and analgesic properties common to other morphine alkaloids and (b) its expression of extreme toxicity and CNS stimulation. Oripavine is also a minor alkaloid of the opium poppy, but it is the main alkaloid of the oriental poppy Papaver orientale, which is a perennial flowering plant. The development of the top1 poppy was an important finding for the opium industry in Australia, because this poppy strain produces thebaine and oripavine, but not morphine or codeine.
    [Show full text]
  • Problems of Drug Dependence 1996: Proceedings of the 58Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. 174 U.S. Department of Health and Human Services • National Institutes of Health Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. Virginia Commonwealth University NIDA Research Monograph 174 1997 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 BOARD OF DIRECTORS Robert L. Balster, Ph.D., President Thomas R. Kosten, M.D. Steven G. Holtzman, Ph.D., President-Elect Michael J. Kuhar, Ph.D. Edward M. Sellers, M.D., Ph.D., Past-President Scott E. Lukas, Ph.D. George E. Bigelow, Ph.D., Treasurer Billy R. Martin, Ph.D. Edgar H. Brenner, J.D. A. Thomas McLellan, Ph.D. Leonard Cook, Ph.D. Roy W. Pickens, Ph.D. Linda B. Cottler, Ph.D, M.P.H. Beny J. Primm, M.D. Linda A. Dykstra, Ph.D. Peter H. Reuter, Ph.D. Avram Goldstein, M.D. Sidney H. Schnoll, M.D., Ph.D. Charles W. Gorodetzky, M.D., Ph.D. Charles R. Schuster, Ph.D. John R. Hughes, M.D. James E. Smith, Ph.D. M. Ross Johnson, Ph.D. Maxine L. Stitzer, Ph.D. EXECUTIVE OFFICER Martin W. Adler, Ph.D. SCIENTIFIC PROGRAM COMMITTEE Thomas R. Kosten, Chair Martin W. Adler Maureen E. Bronson Kathryn A. Cunningham Ellen B. Geller M.
    [Show full text]
  • Benefits and Risks of Pharmaceutical Opioids
    Benefits and risks of pharmaceutical opioids: Essential treatment and diverted medication A global review of availability, extra-medical use, injection and the association with HIV Louisa Degenhardt, Briony Larance, Bradley Mathers, Tasnim Azim, Adeeba Kamarulzaman, Richard Mattick, Samiran Panda, Abdalla Toufik, Mark Tyndall, Lucas Wiessing and Alex Wodak on behalf of the Reference Group to the United Nations on HIV and injecting drug use National Drug and Alcohol Research Centre UNIVERSITY OF NEW SOUTH WALES Sydney, Australia i ISBN: 978-0-7334-2707-7 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. ii Acknowledgements This report is a product of the Reference Group to the United Nations on HIV and injecting drug use and was reviewed by the 2007 members of the Reference Group and also the Secretariat of the Reference Group. In 2007 the Reference Group members were Tasnim Azim, Mauro Guarinieri, Matthew Hickman, Adeeba Kamarulzaman, Kasia Malinowska-Sempruch, Fabio Mesquita, Azarakhsh Mokri, Olanrewaju Olusola Onigbogi, Fred Owiti, Samiran Panda, Steffanie A. Strathdee, Fayzal Sulliman, Abdalla Toufik, Jallal Toufiq, Mark Tyndall and Lucas Wiessing. In 2007 the Secretariat consisted of Richard Mattick, Louisa Degenhardt, Bradley Mathers, Benjamin Phillips, Kate Dolan and Alex Wodak. The following individuals assisted with the compilation of the literature: • Laura Kemmis, United Kingdom • Gabrielle Campbell, NDARC, University of NSW • Eva Congreve, NDARC, University of NSW • Benjamin Phillips, NDARC, University of NSW • Jessica Singleton, NDARC.
    [Show full text]
  • Natural Opioid Peptides, Synthetic Analogs, Peptidases: Pharmacological Analysis and Drug Design
    SEMMELWEIS UNIVERSITY Doctoral School of Pharmaceutical and Pharmacological Sciences NATURAL OPIOID PEPTIDES, SYNTHETIC ANALOGS, PEPTIDASES: PHARMACOLOGICAL ANALYSIS AND DRUG DESIGN by András Z. Rónai Ph.D. Dissertation Supervisor: Prof. Dr. Kálmán Magyar, D.Sc. Member of Hungarian Academy of Sciences Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest Budapest, 2004 1 To Sándor Bajusz 2 CONTENTS 1. Introduction 2. List of abbreviations 3. Results and Conclusions 3.1. Chapter 1. Critical overview of the use of isolated organs in opioid research 3.2. Chapter 2. Pharmacological characterisation of enkephalins, b-endorphin and its fragments 3.3. Chapter 3. Development of potent analgesic enkephalin analogs such as (D-Met2,Pro5) -enkephalinamide 3.4. Chapter 4. Characterisation of structural principles for the receptor type-selectivity of enkephalin analogs 3.5. Chapter 5. Detection of a novel dipeptidyl-carboxypeptidase in rodent blood vessel and human adrenomedullary tumors 3.6. Chapter 6. Design and pharmacological characterisation of novel, pure and highly d -opioid receptor type-selective and k-opioid receptor type.selective peptide antagonists: the principle of N-acylation. 3.7. Chapter 7. Present and future: endomorphins, nociceptin. 4. General summary and conclusions 5. Acknowledgement 6. References 7. Patents 8. Appendix. 3 1. Introduction The cornerstone of opioid peptide history was the discovery of enkephalins (Tyr-Gly-Gly- Phe-Met, (Met5) enkephalin and Tyr-Gly-Gly-Phe-Leu, (Leu5)-enkephalin) in porcine brain by Hughes, Kosterlitz and their coworkers in 1975 (53). The history appeared to obey the principle of receptor theory declaring that a receptor should have one or more endogenous ligand(s).
    [Show full text]
  • Electrospray Tandem Mass Spectrometric Investigations of Morphinans
    Electrospray Tandem Mass Spectrometric Investigations of Morphinans Klaus Raith and Reinhard Neubert Institute of Pharmaceutics and Biopharmaceutics, Martin Luther University, Halle, Germany Chotima Poeaknapo, Christian Boettcher, and Meinhart H. Zenk Biocenter, Martin Luther University, Halle, Germany Ju¨rgen Schmidt Leibniz Institute of Plant Biochemistry, Halle, Germany ϩ In this study positive ESI tandem mass spectra of the [M ϩ H] ions of morphinan alkaloids obtained using an ion trap MS were compared with those from a triple quadrupole MS. This allows to assess the differences of the tandem-in-time versus the tandem-in-space principle, often hampering the development of ESI MS/MS libraries. Fragmentation pathways and possible fragment ion structures were discussed. In order to obtain elemental composition, accurate mass measurements were performed. According to the MS/MS fragmentation pathway, the investigated compounds can be grouped into 4 subsets: (1) morphine and codeine, (2) morphinone, codeinone, and neopinone, (3) thebaine and oripavine, (4) salutaridine and salutaridinol. Salutaridinol-7-O-acetate shows a different fragmentation behavior because of the favored loss of acetic acid. Although most fragment ions occur in both ion trap and triple quad tandem mass spectra, some are exclusively seen in either type. For triple quad, quadrupole time-of-flight and FT-ICR MS/MS, the base peak of morphine results from an ion at m/z 165 that contains neither nitrogen nor oxygen. This ion is not found in ion trap MS/MS, but in subsequential MS3 and MS4. (J Am Soc Mass Spectrom 2003, 14, 1262–1269) © 2003 American Society for Mass Spectrometry espite the importance of morphine and its to magnetic sector instruments, triple quadrupole, biosynthetic relatives, the literature dealing quadrupole ion trap, and quadrupole time-of-flight Dwith electrospray ionization mass spectro- are all considered to perform low collision energy metry is limited.
    [Show full text]
  • Drugs of Abuse: Chemistry, Pharmacology, Immunology, and AIDS, 96
    Drugs of Abuse: Chemistry, Pharmacology, lmmunology, and AIDS U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drup Abuse, and Mental Health Administration Drugs of Abuse: Chemistry, Pharmacology, Immunology, and AIDS Editors: Phuong Thi Kim Pham, Ph.D. Research Technology Branch Division of Preclinical Research National Institute on Drug Abuse Kenner Rice, Ph.D. Laboratory of Medicinal Chemistry National Institute of Diabetes and Digestive and Kidney Diseases NIDA Research Monograph 96 1990 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 Drugs of Abuse: Chemistry, Pharmacology, Immunology, and AIDS ACKNOWLEDGMENT This monograph is based on the papers and discussion from a technical review on “Current Chemical and Pharmacological Advances on Drugs of Abuse Which Alter Immune Function and Their Impact Upon HIV Infec- tion” held on October 31 to November 2, 1988, in Rockville, MD. The review meeting was sponsored by the Office of Science and the Division of Preclinical Research, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]